Loading...
Overview2021-08-31T06:41:29-07:00

Company Profile

Emerald Health Pharmaceuticals is developing innovative, new product candidates with unique targeted mechanisms of action for the treatment of autoimmune, neurodegenerative and other diseases. The company has two families of new chemical entities created through rational drug design to affect validated receptors and pathways in the body pertinent to targeted diseases. Its first drug candidate, EHP-101, is now in Phase 2 clinical trial and is being developed for the treatment of multiple sclerosis and systemic sclerosis. Its second product candidate, EHP-102, is in preclinical development and is focused on treating Huntington’s disease and Parkinson’s disease.

Investor Resources

CORPORATE
PRESENTATION

Presentation
View

FACT
SHEET

Fact Sheet
View

DATA PRESENTATION /
PUBLICATIONS

Data Presentation/Publications
View

PRESS
RELEASES

Press Kit
View

Events

No upcoming events at this time. 
View all events

Investor & Media Inquiries

INVESTOR RELATIONS
1.858.352.0622 | Email | Online Form

MEDIA RELATIONS
1.858.352.0622 | Email | Online Form

Go to Top